Serum Antigen Tests for the Diagnosis of Invasive Aspergillosis: a Retrospective Comparison of Five Antigen Assays and One Beta-D-glucan Assay

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2024 Nov 4

PMID 39494863

Authors

Thilo Schub

Isabel Klugherz

Johannes Wagener

Juergen Prattes

Martin Hoenigl

Sebastian Suerbaum

Jurgen Held

Karl Dichtl

Affiliations

Soon will be listed here.

Abstract

Invasive aspergillosis (IA) is a life-threatening infection. Early and specific diagnosis is pivotal to ensure adequate therapy. Antigen testing from blood is a widespread and convenient diagnostic approach. Various tests for the detection of antigen as well as for the panfungal antigen β-1,3-D-glucan (BDG) are available, for which comprehensive comparisons are still lacking. Blood samples of 82 proven/probable (11/71) IA patients and 52 controls were tested using two enzyme-linked immunosorbent assays (ELISAs) (Bio-Rad and Euroimmun), one chemiluminescent immunoassay (CLIA) (Vircell), one BDG assay (Fujifilm Wako), and two point of care (PoC) assays (Immy sōna and OLM). PoC assays were evaluated visually and used automated read out systems. Of the 82 IA patients, 37 had received solid organ transplantation (SOT) and 25 hematopoietic stem cell transplant (HSCT). Sensitivities and specificities for the eight test systems ranged from 27% to 71% and from 64% to 100%. Estimating a 10% prevalence of IA, test performance would have resulted in positive and negative predictive values of 14%-100% and 91%-95%. Areas under the curve (AUCs) for all tests except GM were below 0.7. When the cut-off values for quantitative tests were normalized to a specificity close to 95%, sensitivities ranged from 14% to 40%. The use of automated read out systems for the PoC assays had a significant impact. Combining different tests did not result in better test strategies. Sensitivity of antigen testing from single serum samples is low. Due to specificity issues, the majority of tests is not suited for screening purposes. The different assays can meet different needs in different diagnostic settings.

References

Dichtl K, Seybold U, Ormanns S, Horns H, Wagener J . Evaluation of a Novel Antigen Enzyme-Linked Immunosorbent Assay. J Clin Microbiol. 2019; 57(7). PMC: 6595454. DOI: 10.1128/JCM.00136-19. View

Bukkems L, Dommelen L, Regis M, van den Heuvel E, Nieuwenhuizen L . The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the Hematological Patient: A Systematic Review and Meta-Analysis. J Fungi (Basel). 2023; 9(6). PMC: 10305130. DOI: 10.3390/jof9060674. View

Almeida-Paes R, Almeida M, de Macedo P, Caceres D, Zancope-Oliveira R . Performance of Two Commercial Assays for the Detection of Serum Galactomannan in Non-Neutropenic Patients. J Fungi (Basel). 2022; 8(7). PMC: 9320752. DOI: 10.3390/jof8070741. View

Ullmann A, Aguado J, Arikan-Akdagli S, Denning D, Groll A, Lagrou K . Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 Suppl 1:e1-e38. DOI: 10.1016/j.cmi.2018.01.002. View

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View

Thornton C, Johnson G, Agrawal S . Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp. 2012; (61). PMC: 3460586. DOI: 10.3791/3721. View

Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M . β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2011; 54(5):633-43. DOI: 10.1093/cid/cir897. View

Chindamporn A, Chakrabarti A, Li R, Sun P, Tan B, Chua M . Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: An Asia Fungal Working Group (AFWG) initiative. Med Mycol. 2017; 56(4):416-425. DOI: 10.1093/mmy/myx066. View

Aerts R, Mercier T, Houben E, Schauwvlieghe A, Lagrou K, Maertens J . Performance of the JF5-Based Galactomannoprotein EIA Compared to the Lateral Flow Device and the Galactomannan EIA in Serum and Bronchoalveolar Lavage Fluid. J Clin Microbiol. 2022; 60(11):e0094822. PMC: 9667759. DOI: 10.1128/jcm.00948-22. View

10.

Mercier T, Dunbar A, Veldhuizen V, Holtappels M, Schauwvlieghe A, Maertens J . Point of care aspergillus testing in intensive care patients. Crit Care. 2020; 24(1):642. PMC: 7652676. DOI: 10.1186/s13054-020-03367-7. View

11.

Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S . Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological.... J Clin Microbiol. 2004; 42(6):2733-41. PMC: 427860. DOI: 10.1128/JCM.42.6.2733-2741.2004. View

12.

Koulenti D, Papathanakos G, Blot S . Invasive pulmonary aspergillosis in the ICU: tale of a broadening risk profile. Curr Opin Crit Care. 2023; 29(5):463-469. DOI: 10.1097/MCC.0000000000001070. View

13.

Driemeyer C, Falci D, Oladele R, Bongomin F, Ocansey B, Govender N . The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe. 2022; 3(6):e464-e470. DOI: 10.1016/S2666-5247(21)00190-7. View

14.

Zhang L, Guo Z, Xie S, Zhou J, Chen G, Feng J . The performance of galactomannan in combination with 1,3-β-D-glucan or aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: Evidences from 13 studies. Diagn Microbiol Infect Dis. 2018; 93(1):44-53. DOI: 10.1016/j.diagmicrobio.2018.08.005. View

15.

Douglas A, Smibert O, Bajel A, Halliday C, Lavee O, McMullan B . Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021; 51 Suppl 7:143-176. DOI: 10.1111/imj.15591. View

16.

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

17.

Mikulska M, Balletto E, Castagnola E, Mularoni A . Beta-D-Glucan in Patients with Haematological Malignancies. J Fungi (Basel). 2021; 7(12). PMC: 8706797. DOI: 10.3390/jof7121046. View

18.

De Carolis E, Marchionni F, Torelli R, Angela M, Pagano L, Murri R . Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases. PLoS One. 2020; 15(7):e0236095. PMC: 7390339. DOI: 10.1371/journal.pone.0236095. View

19.

Hoenigl M, Egger M, Boyer J, Schulz E, Prattes J, Jenks J . Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two-centre mixed cohort study. Mycoses. 2021; 64(10):1197-1202. PMC: 8518476. DOI: 10.1111/myc.13352. View

20.

Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J . Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect. 2018; 77(3):235-241. PMC: 6097945. DOI: 10.1016/j.jinf.2018.05.001. View